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Objective: To evaluate clinical outcomes and postoperative quality of life in patients affected by locally
advanced ovarian cancer who underwent pelvic posterior exenteration with Hudson-Delle Piane radical
retrograde hysterectomy.
Materials and Methods: Our study was done on a retrospective cohort using data from 22 patients who
underwent surgery between 2010 and 2014 at the Gynecological Oncologic Center of Parma, Parma, Italy.
Results: Residual disease after surgery (Sugarbacker index) was absent (CC-0) in 68% of cases. Tumor size
was < 2.5 mm (CC-1) in 14% of cases and between 2.5 mm and 2.5 cm (CC-2) in 18% of cases. Compli-
cations during surgical procedure occurred in 64% of patients (14/22), but without severe consequences.
Immediate postoperative complications ( 30 days) occurred in 82% of patients (18/22), and delayed
complications (> 30 days) occurred in 23% (5/22) of patients. No patient died because of a complication.
Urinary and rectal incontinence occurred in 5% and 16% of patients, respectively. Disease recurrence
occurred in 58% of patients, median disease-free survival was 14 months (range, 6e36 months), and
median overall survival was 21 months (range, 6e42 months).
Conclusion: Our study conﬁrmed that pelvic posterior exenteration associated with retrograde radical
hysterectomy represents the safest radical surgical approach to advanced ovarian cancer, which permits
preservation of the pelvic autonomic nerve plexus and, therefore, bladder and colorectal functions.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Epithelial ovarian cancer (EOC) is the sixth most common ma-
lignancy among women in developed countries, with an estimated
incidence of 100,300 new cases per year [1,2]. The standard treat-
ment remains primary cytoreductive surgery [primary debulking
surgery (PDS)], followed by different cycles of adjuvant platinum-
based chemotherapy [3,4]. A primary approach based on interval
debulking surgery (IDS) following neoadjuvant chemotherapy may
be appropriate, especially in patients whose medical conditions do
not permit primary surgery. Evidence concerning survival rates,d Gynaecology, Gynaecologic
io Gramsci 14, 43126 Parma,
. Berretta).
bstetrics & Gynecology. Publishedadverse events, and quality of life in patients subjected to this
approach are still inconclusive [5,6].
Brunshwing et al [7], with a primary palliative intent, intro-
duced the concept of pelvic exenteration (PE) in the treatment of
advanced pelvic cancer. Occasionally, PE unexpectedly resulted in a
long-term survival and permitted a deﬁnition of the surgical
technique and the criteria for correctly selecting patients that
would beneﬁt from this extensive surgery [8].
PE is classiﬁedasanterior (APE),posterior (PPE), or total (TPE).APE
consists of the removal of both reproductive tract and bladder, PPE
consists of the removal of the reproductive tract along with recto-
sigmoid colon, and TPE involves removing all anatomical structures
listed above. Regarding the level of resection of pelvic viscera, we
subclassify PE as supraelevator (above the levator muscle), infraele-
vator (preservation or resection of levator muscle), and with vul-
vectomy (extension or resection of the uro-genital diaphragm) [9,10].by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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neal approach is designed for intact removal of aﬁxed ovarian-tumor
en-bloc of the attached peritoneum, uterus, recto-sigmoid, and all
surrounding structure [11e13]. Recent studies analyzing PPE efﬁcacy
and safety for the treatment of locally advanced EOC reported an
overall survival raging between 33 months and 49.4 months after
surgery, conﬁrming that PE represents a feasible surgical option of-
feringanacceptable prognosis tohighly selectedpatientswith locally
advanced-stage EOC [14e16].
Despite general agreement in describing the rates of intra-
operative and early postoperative complication at ~30%,
[8,9,17,18], little data are currently available concerning long-term
complications, patient quality of life, and especially long-term ef-
fects of PPE on residual rectal and bladder functions. The aim of this
study was to evaluate the onset of intra- and postoperative com-
plications (both early and late complications), with particular
attention to residual bladder and rectal functions 6-months post-
surgery in patients with locally advanced EOC who underwent,
by retroperitoneal approach, PDS or IDS with nerve-sparing PPE
and retrograde radical hysterectomy according to the Hudson-Delle
Piane (IRHDP) technique.
Materials and methods
We performed an observational, retrospective, cohort study on
womenwhounderwentPPE for locallyadvancedEOCoveraperiodof
4 years between October 2010 and September 2014 at the Gynecol-
ogyandObstetrics Clinic, Departmentof Surgical Sciences, University
of Parma, Parma, Italy. All patients agreed to the aim of the study and
to the use of their data according to Italian Privacy Law (675/96).
We included patients < 82 years of age with an anesthetic risk
3 (ASA  3) and affected by primary EOC (independently from
histotype) at stages II, III, or IV according to International Federa-
tion of Gynecology and Obstetrics (FIGO) classiﬁcation [6] who
underwent nerve-sparing PPE and IRHDP. All included patients
presented with a pouch of Douglas or rectal involvement due to the
direct extension of the neoplasm or serosal implantation. All pa-
tients underwent a laparoscopic stadiation, and a Fagotti score was
applied. Those with a favorable score (< 8) underwent primary
cytoreduction. When the score was > 8, IDS was performed after
neoadiuvant chemotherapy [19,20].
In addition to PPE, standard-staging procedures (omentectomy,
selective pelvic and lobo-aortic bulky node removal, peritoneal bi-
opsies) and, in some cases, additional aggressive surgical procedures,
including intestinal segment resections, peritonectomy, and splenec-
tomy, were performed in order to achieve a complete cytoreduction.
For all patients, we collected data regarding age, parity, body
mass index (BMI), pre-operative CA-125 serum value, stage and
histotype of the disease, and timing of surgical operation (PDS or
IDS). We also collected intra-operative data, including blood loss,
operative time, need of blood transfusions, residual disease (RD)
evaluated according to the Sugarbaker index [21], and intra-
operative complications based on Clavien-Dindo classiﬁcation
[22]. The postoperative data collected included length of hospital-
ization, postoperative complications divided into early (< 30 days)
and late (> 30 days) according to Clavien-Dindo classiﬁcation, re-
sidual rectal and bladder functioning at 6-months post-surgery,
residual rectal and bladder functions > 6-months post-surgery,
recurrence rate, disease-free survival (DFS), overall survival (OS),
and mortality index due to disease progression.
Evaluation of postoperative residual rectal and bladder function
To evaluate residual bladder function, all patients were asked to
complete the validated short version of the Urogenital DistressInventory (UDI-6) questionnaire at 6-months post-surgery in order
to detect any urinary disorders [23]. To evaluate residual rectal
function, all patients were required to complete the validated Fecal
Incontinence Severity Index (FISI) questionnaire at 6-months post-
surgery, which allows detection of fecal incontinence disorder
based on gas, mucus, solid, or liquid stools [24].Surgical procedure
The ﬁrst stage of the surgical procedure began with a longitu-
dinal suprapubic incision and an exhaustive exploration of the
abdominal cavity to evaluate the extent of the disease and possible
contraindication for surgery (invasion of the mesenteric root, celiac
region, hepatic pedicle, gastric serous membrane, the presence of
peritoneal miliaria, or multiple inoperable tumor sites in the
bowel). After abdomen and pelvic inspection, all patients under-
went en-bloc PPE and IRHDP as follows. The retroperitoneal
approach began with the bilateral ligation and section of uterine
round and infundibulopelvic ligaments, the isolation of ureters to
the bladder, the uterine artery, the iliac vessels, and the obliterated
artery, with subsequent opening of pararectal spaces of Latzko and
Okabayashi and of medial paravesical and Yabuki spaces [25,26].
After the identiﬁcation of hypogastric nerves (which run ~2 cm
below the ureters), the lateral pelvic peritoneum and bladder
peritoneum were opened, creating a peritoneal ﬂap that is cleaved
from the bladder proceeding caudally toward the vesico-vaginal
space. At the upper third of the vagina, the surgeon performed an
anterior and then a posterior colpotomy, with the opening of recto-
vaginal space to the rectal ampulla. The operation proceeded
laterally, with the execution of a radical hysterectomy, type C1
(with nerve preservation), according to the classiﬁcation of
Querleu-Morrow (Figures 1 and 2) [27].
To perform the contemporary en-bloc resection of the rectum,
the surgeon proceeded to the development of pararectal fossae and
the retrorectal spaces with the isolation of Waldeyer’s fascia, hy-
pogastric nerves, and the superior pelvic plexus. The rectosigmoid
was mobilized from its peritoneal attachments and divided 3e5 cm
above the disease using a linear mechanic stapler (Endo GIA™,
Convidien), followed by its being freed from its mesentery and
divided below the disease process, allowing for en-bloc removal of
the entire pelvic disease. Finally, an end-to-end anastomosis with a
circular stapler (EEA™, Convidien) inserted into the anus was
performed. Prophylactic ileostomy or colostomy was performed in
cases of ultralow resection.Results
Twenty two patients were eligible for the clinical study, with a
mean age of 65 years (range, 47e82 years) and a mean BMI of 27
(range, 20.1e33.1). Pre-operative serum CA-125 levels were above
normal in 81.8% of patients (mean, 1375.82 U/mL). Seventeen pa-
tients (77%) underwent PDS, followed by adjuvant chemotherapy.
Only 23% of these (5 patients) underwent IDS following neo-
adjuvant chemotherapy [4e6 cycles of Carboplatin (area under
the curve ¼ 5) and 175 mg/mq Paclitaxel]. The average length of
hospital stay was 16 days (range, 8e34 days), with a median of 13
days.
According to FIGO classiﬁcation, stage IV patients accounted for
41% of all cases (9 patients), stage III-C accounted for 54% of all cases
(12 patients), and only one patient presentedwith stage II-C disease
at deﬁnitive diagnosis. Histological patterns for 95% of patients (21
cases) showed deﬁnitive diagnosis of high-grade serous carcinoma,
with only one patient presenting with low-grade carcinoma.
Detailed data are shown in Table 1.
Table 1
Patient characteristics.
Characteristics
No. patients 22
Age (mean), y 65
BMI (mean) 27
Parity
Nulliparity 36.4
Multiparity 63.6
Pre-operative Ca-125 serum:
<1500 U/mL 81
>1500 U/mL 19
Histotype:
High-grade serous carcinoma 95
Low-grade carcinoma 5
FIGO stage:
FIGO stage IV 41
FIGO stage IIIC 54
FIGO stage IIC 5
Data are presented as %, unless otherwise indicated.
FIGO ¼ International Federation of Gynecology and Obstetrics.
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tients), with left-hemicolectomy in 59% of cases (13 patients), total
colectomy in 9% of cases (2 patients), and last ileal loop resection in
14% of cases (3 patients). After an end-to-end anastomosis, 18% of
patients underwent prophylactic stoma, including ileostomy (1
patient) or colostomy (3 patients). Patients (68%; 15 cases) under-
went pelvic lymphadenectomy. The mean number of lymph nodes
removed was 16 (range, 2e42), and in eight patients (53%), they
tested positive for metastatic involvement. Moreover, only 16 pa-
tients (73%) underwent selective lombo-aortic lymphadenectomy,
with themean number of lombo-aortic lymph nodes removed at 15
(range, 2e49), with positivity to metastatic spread detected in nine
patients (56%). Six patients (27%) underwent splenectomy.
Sixteen patients (73%) required a partial resection of the dia-
phragmatic peritoneum due to metastatic spread (on the right side
in 9 patients, the left side in 1 patient, and bilateral in 6 patients).
Detailed data about concomitant surgical procedures necessary for
complete cytoreduction are reported in Table 2.
The mean operative time was 520 min (range, 210e700 min),
with a mean blood loss of 1100 mL (range, 800e2500 mL). The RD
after surgery, according to the Sugarbaker index, was absent (CC-
0) in 68% of cases, > 2.5 mm (CC-1) in 14% of cases, and between
2.5 mm and 2.5 cm (CC-2) in 18% of cases. We reported an intra-
operative complication rate of 64% (14 patients). In 23% of cases
(5 patients), an intra-operative hemorrhage (> 1500 cc) requiring
packed blood-cell transfusion (a Grade-II complication based on
Clavien-Dindo classiﬁcation). Nine patients (41%) were affected
by Grade-III complications requiring adjunctive-surgical pro-
cedures, and in particular, eight patients experienced anTable 2
Surgical procedures in addition to IRHDP and rectosigmoid resection.
Type of surgical procedure
Left-hemicolectomy
Total colectomy
Last ileal loop resection
Ileostomy
Colostomy
Pelvic lymphadenectomy
Lombo-aortic lymphadenectomy
Omentectomy
Splenectomy
Resection of the peritoneum of the diaphragmatic cupola
IDS ¼ interval debulking surgery; IRDHP ¼ IDS with nerve-sparing PPE a
Piane technique; PPE ¼ posterior pelvic exenteration.iatrogenic diaphragmatic lesion during peritonectomy without
opening the pleural cavity. In one patient, we reported an iatro-
genic bladder lesion. All surgical lesions were promptly repaired
and sutured.
Concerning early postoperative complications ( 30 days), we
reported a total complication rate of 82% (18 patients), with 16
episodes classiﬁable as Grade-I or -II and eight episodes as Grade-III
or -IV. Of the Grade-I and -II complications, we described three
episodes of mild pleural effusion successfully treated by noninva-
sive mechanical ventilation and respiratory physiotherapy (Grade-
I), nine episodes of worsening anemia (hemoglobin < 8 g/dL) that
required packed blood-cell transfusion (Grade-II), two episodes of
persistent hyperpyrexia (> 38C) that required prolonged antibiotic
therapy, one episode of bowel subocclusion requiring hospitaliza-
tion, but not a second surgical procedure (Grade-II), and one
episode of paresthesia of the left thigh successfully treated by
corticosteroids (Grade-II). However, of the Grade-III and -IV com-
plications, four patients underwent a second surgical laparotomy
procedure due to one episode of peri-anastomotic ﬁstula that
required the performance of a colostomy, one episode of gastric
perforation secondary to a pyloric ulcer successfully treated by
suturing the gastric wall, and two episodes of anastomotic leakage
that required performance of a total colectomy with a deﬁnitive
ileostomy. Moreover, we reported one case of pulmonary throm-
boembolism that required transfer to the Intensive Care Unit.
Concerning late postoperative complications (> 30 days), we
reported a total complication rate of 23% (5 patients). One patient
presented with a Clostridium difﬁcile infection (Grade-II) that was
adequately treated with antibiotics, two patients showed an inci-
sional hernia (Grade-IIIB), one patient had an episode of symp-
tomatic lymphocele drained under sonographic guidance (Grade-
IIIA), and one patient underwent a re-laparotomy for bowel oc-
clusion due to postoperative adhesions that required an ileal
resection (Grade-IIIB). We reported no cases of mortality due to
postoperative complications. Detailed data regarding postoperative
complications are reported in Table 3.
During the follow-up period (range, 6e47 months), we reported
a median DFS of 14.3 months (range, 6e36 months) and a median
OS of 21 months (range, 6e47 months). Eleven patients (58%)
developed disease recurrence over a range of time between 6
months and 36 months, with a mean of 14.3 months. However we
did not report cases of pelvic disease relapse. During the follow-up
period, we detected subsequent extrapelvic metastases localization
in four cases (peritoneal), three cases (aortic lymph nodal), three
cases (hepatic), and one case of pulmonary involvement. The
mortality index for the sample was 23% (5 patients) due to disease
progression and recurrence.
Regarding residual bladder function at 6-months post-surgery,
we reported only one case of moderate urinary distress symp-
toms according to UDI-6, with the patient reporting a total score ofNo. patients Cases (%)
13 56
2 9
3 14
1 0.22
3 14
15 68
16 73
22 100
6 27%
16 73
nd retrograde radical hysterectomy according to the Hudson-Delle
Table 3
Intra-operative and postoperative complications.
No. patients Cases (%)
Intra-operative complications
Hemorrhage (>1500 cc) 5 23
Iatrogenic diaphragmatic lesion 8 53
Iatrogenic bladder lesion 1 0.22
Early postoperative complications ( 30 d)
Pleural effusion 3 14
Anemia (Hb <8 g/dL) 9
Hyperpyrexia (>38C) 5 23
Bowel subocclusion 1 0.22
Left-thigh paresthesia 1 0.22
Peri-anastomotic ﬁstula 1 0.22
Anastomotic leak 2 9
Gastric laceration 1 0.22
Pulmonary thromboembolism 1 0.22
Late postoperative complications (> 30 d)
Clostridium difﬁcile infection 1 0.22
Incisional hernia 2 9
Lymphocele 1 0.22
Bowel occlusion 1 0.22
Hb ¼ hemoglobin.
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continence 6-months post-treatment.
Regarding residual rectal function evaluated by FISI question-
naire > 6 months post-surgery, only one patient reported fecal
incontinence twice weekly or more. One patient experienced
moderate constipation, likely related to adjuvant chemotherapy
treatment. We did not report any other cases of rectal function
abnormalities. We excluded from rectal function evaluation pa-
tients who underwent total colectomy, a single case that required a
deﬁnitive ileostomy, and all cases that required a second surgical
procedure on the bowel due to postoperative complications (a total
of 6 patients were excluded). During the early postoperative period,
all patients had regular micturion, and any intermittent catheteri-
zationwas required. Urinary and rectal incontinence occurred in 5%
and 16% of patients, respectively.Discussion
The pivotal point of EOC treatment is to obtain an optimal sur-
gical cytoreduction, which is one of the most powerful predictors of
DFS and OS in advanced stages of disease [28,29]. DFS and OS are
signiﬁcantly worse in patients with suboptimal debulking, and
evidence does not demonstrate a survival beneﬁt for a secondary
cytoreductive procedure when an adequate attempt at primary
debulking was undertaken [30]. Due to the anatomical continuity
between rectum and uterus, it is not unusual in locally advanced
EOCs to observe widespread involvement of rectosigmoid, adjacent
peritoneum, anterior, or especially posterior pelvic compartments
[15]. In light of this data, PE and, especially, PPE with a retroperi-
toneal approach that allows for total en-bloc resection of pelvic
posterior compartment organs ideally should represent the most
effective surgical procedure for achieving optimal debulking. Even
given the heterogeneous results and those related to poor sample
sizes and the retrospective design of almost all available literature
on this topic, the efﬁcacy of PPE has been conﬁrmed by different
studies describing median OS ranging between 27 months and 50
months and median DFS ranging between 18 months and 50
months in patients affected by stage IIIeIV EOC treated by PPE.
[14e16,28,31e34]. In our study, we reported a DFS and OS that were
slightly lower as compared to those reported in previously; how-
ever, this result may be explained by only four patients (18%) un-
dergoing a 6-month follow-up.Even if the efﬁcacy of PPE in terms of OS and DFS is generally
conﬁrmed, the complication rate related to this surgical procedure
is still very high. In our study, we reported an intra-operative
complication rate of ~64% and a postoperative complication rate
of ~82%. These data seem high as compared to previous studies;
however, we emphasize that the majority of those studies analyzed
only the most serious intra-operative and early postoperative
complications, ignoring minor cases that affect overall patient
quality of life [14,31,32]. Taking into account the most serious
complications described (small-bowel obstruction, anastomotic
leakage, enterocutaneous ﬁstula, pelvic abscess, surgical site
infection, sepsis, and thromboembolic events) [31,32], our data
appear in agreement with available literature, describing a total of
11 patients affected by a Grade-III or eIV postoperative complica-
tions, of which the most serious involved three episodes of anas-
tomotic ﬁstulae, two episodes of anastomotic leakage, one episode
of gastric perforation, one case of pulmonary thromboembolism,
and one episode of bowel occlusion.
In our study, we included in the follow-up period the evaluation
of residual bladder and rectal function at 6-months post-surgery. In
our opinion, this is a very important for the evaluation of post-
surgical patient quality of life. To our knowledge, bladder and
rectal function after PPE for primary gynecological cancer, to the
extent of pelvic autonomic nerve preservation, has not been well
described, even in cases where lesions on the pelvic autonomic
nerves are common complications associated with gynecologic
surgery [35,36]. Where possible, all surgical interventions were
performed with nerve-sparing techniques, saving the pelvic plexus
upper and hypogastric nerves and allowing patients to maintain
good bladder and rectal function. Through the administration of the
validated UDI-6 and FISI questionnaires at 6-months post-surgery,
we detected only two cases of moderate bladder and rectal
dysfunction, respectively. These data are in agreement with the
only available paper that evaluated residual bladder functioning
after PPE using a nerve-sparing technique [37]. Given that the
sample size of our studywas too small to draw any ﬁnal conclusions
regarding the real value of this technique in preserving rectal and
bladder function, future large-scale studies on this topic are
required to validate these ﬁndings.
In conclusion, our data suggested that a nerve-sparing PPE and
retrograde radical hysterectomy according to the IRHDP technique
represents an effective surgical option in cases of locally advanced
EOC. This procedure allows for minimization of metastatic perito-
neal spread, ensuring an optimal cytoreduction and acceptable re-
sidual bladder and rectal function at 6-months post-surgery. The
high rate of intra- and postoperative complications suggested that
more efforts should be undertaken in pre-operative selection of
patients who could beneﬁt from this extensive surgery. A multi-
disciplinary approach between gynecologist, general surgeon, and
oncologist remains pivotal to reducing complication rates and
maximizing the efﬁcacy and safety of this aggressive surgical option.
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